AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32819390
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (ACT) consisting of 8 cycles of capecitabine plus oxaliplatin
Trial: 35551928
Drug: Alcohol (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (target breath alcohol content [BrAC] 80 mg/dL) and placebo cannabis
Trial: 32568799
Drug: Novel technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel technique using a partial-thickness hinge punch for DMEK graft preparation
Trial: 34215712
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy Program (8 sessions, 90 to 120 minutes each, over 8 weeks)
Trial: 32389476
Drug: Multi‐step gradual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi‐step gradual weaning program (MG)
Trial: 32389476
Drug: ADJ treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADJ treatment
Trial: 33485703
Drug: Topical zinc
RxNorm normalized name: bacitracin topical zinc compounding powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical zinc sulphate (n = 20)
Trial: 34955298
Drug: Reflexology Massage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reflexology Massage with Passive Music Therapy
Trial: 34704354
Drug: Atipamezole (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atipamezole (0.2 mg/kg)
Trial: 34704354
Drug: Flumazenil (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (0.1 mg/kg)
Trial: 34704354
Drug: 4-Aminopyridine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-Aminopyridine (0.5 mg/kg)
Trial: 34704354
Drug: Control (physiological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (physiological saline solution at 0.1 mL/kg)
Trial: 33032804
Drug: Subarachnoid morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subarachnoid morphine (100 μg)
Trial: 33032804
Drug: Femoral Nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Femoral Nerve Block (BNF) with 25 mL of 0.375% ropivacaine
Trial: 33032804
Drug: Femoral Nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Femoral Nerve Block (BNF) with 25 mL of 0.25% ropivacaine
Trial: 35777186
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg Q3W
Trial: 33546942
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose anthocyanins (201 mg)
Trial: 33546942
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose anthocyanins (47 mg)
Trial: 33198608
Drug: Ticagrelor (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (180 mg loading dose on day 1 followed by 90 mg twice daily for days 2-30) added to aspirin (300-325 mg on day 1 followed by 75-100 mg daily for days 2-30)
Trial: 33198608
Drug: Placebo added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo added to aspirin (300-325 mg on day 1 followed by 75-100 mg daily for days 2-30)
Trial: 33346782
Drug: Ticagrelor added
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor added to aspirin
Trial: 33115598
Drug: CBJ with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBJ with 1000 mg of vitamin C (NC)
Trial: 32524145
Drug: Ultrasound‐mediated transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound‐mediated transdermal drug delivery (group U)
Trial: 32524145
Drug: Lidocaine intradermal
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine intradermal injection (group I)
Trial: 38587241
Drug: No beta-blocker
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No beta-blocker treatment
Trial: 33267853
Drug: Additional substances
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional substances daily, khat dependency, early age initiation of khat chewing
Trial: 33748282
Drug: Etoricoxib 60
RxNorm normalized name: etoricoxib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 60 mg orally 30 min before surgery
Trial: 34708399
Drug: Cannabis-based medicine
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis-based medicine (CBM)
Trial: 35946240
Drug: 0.5% minocycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% minocycline mouth rinse prescribed along with vitamin supplement and topical anesthetic gel
Trial: 35946240
Drug: Topical anesthetic
RxNorm normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical anesthetic gel and vitamin supplement alone
Trial: 35381095
Drug: Imeglimin (IMEG)
RxNorm normalized name: Fosaprepitant Dimeglumine
DrugBank: Imeglimin (DB12509)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Imeglimin (IMEG) at 1000- and 1500-mg doses twice daily
Trial: 33827289
Drug: Possible treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Possible treatment for children with profound autism
Trial: 35181572
Drug: APT‐1011 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APT‐1011 3 mg twice daily (BID)
Trial: 35181572
Drug: APT‐1011 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APT‐1011 3 mg at bedtime (HS)
Trial: 35181572
Drug: APT‐1011 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APT‐1011 1.5 mg BID
Trial: 35181572
Drug: APT‐1011 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APT‐1011 1.5 mg HS
Trial: 35181572
Drug: APT‐1011 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APT‐1011 3 mg BID
Trial: 35181572
Drug: APT‐1011 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APT‐1011 3 mg HS
Trial: 33966331
Drug: HBVaxPro®-10 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBVaxPro®-10 µg
Trial: 34864978
Drug: Ultraslow thrombolytic
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultraslow thrombolytic regimen (25 mg of rtPA infused in 25h)
Trial: 34864978
Drug: Fast thrombolytic
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast thrombolytic regimen (50 mg of rtPA infused in 6h)
Trial: 33107745
Drug: IV administration
RxNorm normalized name: IV Administration Set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV administration of cefquinome sulfate (2 mg/kg)
Trial: 33107745
Drug: IM administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IM administration of injectable cefquinome sulfate (2 mg/kg)
Trial: 33107745
Drug: IM administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IM administration of injectable cefquinome sulfate suspension (2 mg/kg)
Trial: 38038626
Drug: Cervarix vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervarix vaccine
Trial: 34621044
Drug: Cabozantinib 60
RxNorm normalized name: cabozantinib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 60 mg orally every day
Trial: 33440015
Drug: I-gel® supraglottic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I-gel® supraglottic airway device
Trial: 32266599
Drug: Vancomycin 15
RxNorm normalized name: vancomycin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin 15 mg/kg every 12 h
Trial: 32266599
Drug: Vancomycin 12
RxNorm normalized name: vancomycin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin 12 mg/kg every 8 h
Trial: 32594832
Drug: Home-based occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based occupational therapy telerehabilitation via smartphone (Caspar Health e-system and mobile app)
Trial: 33595142
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (BoNT‐A) 100 IU/2 mL in each adductor magnus and each triceps surae
Trial: 33595142
Drug: Saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 0.9% (2 mL)
Trial: 33471640
Drug: DPP-4 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DPP-4 inhibitors alone
Trial: 33471640
Drug: DPP-4 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DPP-4 inhibitors plus basal insulin
Trial: 32213768
Drug: Na2FPO3/CaCO3 toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Na2FPO3/CaCO3 toothpaste with 1,378 microg F/g of total soluble fluoride (TSF)
Trial: 32213768
Drug: Aged toothpaste
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aged toothpaste with 1,160 microg F/g TSF
Trial: 32213768
Drug: Aged toothpaste
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aged toothpaste with 900 microg F/g TSF
Trial: 32213768
Drug: Aged toothpaste
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aged toothpaste with 597 microg F/g TSF
Trial: 34028359
Drug: Health care
RxNorm normalized name: Health Care Lancing Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health care mode exercise prescriptions
Trial: 34028359
Drug: Scientific fitness
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scientific fitness mode exercise prescriptions
Trial: 37979959
Drug: Prednisone taper
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone taper
Trial: 32990919
Drug: Peg‐IFN monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peg‐IFN monotherapy
Trial: 34052096
Drug: SHBG-raising therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHBG-raising therapies
Trial: 35766658
Drug: Telemedicine intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telemedicine intervention with daily multidisciplinary rounds by remote intensivists
Trial: 33413462
Drug: EAA +
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EAA + W (34.7 g protein, 24 g EAA)
Trial: 33413462
Drug: MEAL (34.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEAL (34.7 g protein, 11.4 g EAA)
Trial: 33118602
Drug: THC-rich cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC-rich cannabis oil (24.44 mg/mL of THC and 0.51 mg/mL of CBD), initial dose of one drop (∼1.22 mg of THC and 0.02 mg of CBD) a day, increased according to symptoms
Trial: 36258217
Drug: TCM granules
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TCM granules combined with PPI step-down therapy
Trial: 36258217
Drug: TCM granules
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TCM granules placebo combined with PPI step-down therapy
Trial: 34793265
Drug: CJC-1134-PC (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CJC-1134-PC (2 mg single dose or titrated doses of 2 + 3 and 2 + 3 + 4 mg at weekly intervals)
Trial: 34793265
Drug: CJC-1134-PC (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CJC-1134-PC (1, 2, 3, and 4 mg weekly doses)
Trial: 32946978
Drug: First set
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First set of coated tablets
Trial: 32946978
Drug: Second set
RxNorm normalized name: Second Set 42"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second set of coated tablets
Trial: 32556157
Drug: E +
RxNorm normalized name: Perle +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E + sVIP (entecavir + peg‐IFN alfa‐2a [180 µg every week over 48 weeks] plus sequential HBV vaccination [20 µg of HBsAg on weeks 52, 56, 60, and 76])
Trial: 32443306
Drug: Luofengning granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luofengning granule (LFN‐G)
Trial: 32348624
Drug: Guided Biofilm
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Guided Biofilm therapy (GBT) with plaque disclosing agent
Trial: 32348624
Drug: Control without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control without plaque disclosing agent
Trial: 35551292
Drug: Dorzagliatin add-on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzagliatin add-on therapy to metformin (1,500 mg per day)
Trial: 35551292
Drug: Placebo add-on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo add-on therapy to metformin (1,500 mg per day)
Trial: 32713349
Drug: 3R intervention
RxNorm normalized name: (2S,3R)-(-)-Threonine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3R intervention (two facilitated group education sessions, 44 weeks of medication reminders, motivational text messages, and two coaching calls)
Trial: 38505522
Drug: Abaloparatide 80
RxNorm normalized name: ABALOPARATIDE 80MCG/0.04ML PEN 1.56ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abaloparatide 80 μg
Trial: 35231563
Drug: Motion cohort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motion cohort (tibial implant taken through gentle range of motion)
Trial: 32546975
Drug: Midazolam (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.02 mg/kg)
Trial: 32546975
Drug: Control (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (20 mL intravenous saline)
Trial: 34492709
Drug: 6-month cycling
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month cycling aerobic exercise intervention (thrice weekly, moderate-vigorous intensity)
Trial: 34492709
Drug: Aerobic exercise
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic exercise dose
Trial: 35839558
Drug: N-Acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-Acetylcysteine (NAC) 2400 mg daily
Trial: 35583273
Drug: GSK2330811 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2330811 100 mg
Trial: 35583273
Drug: GSK2330811 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2330811 300 mg
Trial: 33408274
Drug: 3-dose schedule
RxNorm normalized name: hepatitis A vaccine, pediatric/adolescent dosage, 3 dose schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-dose schedule (0, 1, and 6 months) of 20 µg rHBV vaccine IM
Trial: 33408274
Drug: 4-dose schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-dose schedule (0, 1, 2 and 6 months) of 20 µg rHBV vaccine IM
Trial: 33408274
Drug: Accelerated 3-dose
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated 3-dose schedule (0, 1, 2 months) of 20 µg rHBV vaccine IM
Trial: 32286685
Drug: Tablet-based intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet-based intervention with audiovisual presentation on coping strategies
Trial: 33307783
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy and exercise (group I)
Trial: 33307783
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy only (group III)
Trial: 34732139
Drug: LPO-system-lozenge with
RxNorm normalized name: N Ice with Vitamin C Lozenge Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPO-system-lozenge with 0.083% H2O2 (B)
Trial: 34732139
Drug: LPO-system-lozenge with
RxNorm normalized name: N Ice with Vitamin C Lozenge Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPO-system-lozenge with 0.04% H2O2 (C)
Trial: 34732139
Drug: Placebo lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lozenge (D)
Trial: 35554097
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg CU+
Trial: 35554097
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg CU+
Trial: 35554097
Drug: STE (1900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STE (1900 mg)
Trial: 32457071
Drug: Cabergoline (dopamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline (dopamine D2 receptor agonist)
Trial: 33933112
Drug: Early childhood
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early childhood education machine (uniform type) in addition to routine standard treatment and nursing
Trial: 33933112
Drug: Routine standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine standard treatment and nursing
Trial: 36402276
Drug: Mobile health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile health application with relational agent
Trial: 32830332
Drug: Polytherapy (Bright
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polytherapy (Bright Light Therapy + Escitalopram Oxalate)
Trial: 32830332
Drug: Monotherapy (Escitalopram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (Escitalopram Oxalate only)
Trial: 32830332
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Polytherapy and Monotherapy)
Trial: 32336721
Drug: Emerging new
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emerging new therapeutic strategies using proprotein convertase subtilisin‐kexin type 9 inhibitors or antisesnse oligonucleotide technology
Trial: 32336721
Drug: Conventional pharmacological
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional pharmacological therapies (statin, niacin, cholesteryl ester transfer protein)
Trial: 33765997
Drug: Non-suppression of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-suppression of viral load (>1000 copies/mL)
Trial: 33765997
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy of ≥1 year
Trial: 33765997
Drug: Self-reported better
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported better adherence to antiretroviral drugs
Trial: 33605836
Drug: Cinnamon (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnamon (3 g capsules)
Trial: 32726531
Drug: TY014 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TY014 (2 mg/kg)
Trial: 32726531
Drug: TY014 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TY014 (20 mg/kg)
Trial: 35777058
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL of 2% mepivacaine (group M)
Trial: 32070396
Drug: Multi-family therapy
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-family therapy (MFT)
Trial: 32070396
Drug: Systemic single-family
RxNorm normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic single-family therapy (SFT)
Trial: 33112463
Drug: Topical herbal
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical herbal solution (MTS + THS)
Trial: 33229019
Drug: Life Goals
RxNorm normalized name: Life-O-Gen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Life Goals Programme (LGP) - six weekly group sessions
Trial: 32907801
Drug: Tapering TNF-inhibitor
RxNorm normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapering TNF-inhibitor first
Trial: 32907801
Drug: Tapering csDMARD
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapering csDMARD first
Trial: 38296197
Drug: Adjunctive Reflectance
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive Reflectance Confocal Microscopy (RCM)
Trial: 32098536
Drug: Conventional incubator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional incubator (K‐System G‐185 Flatbed)
Trial: 33942350
Drug: Postdiagnosis aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postdiagnosis aspirin use
Trial: 33942350
Drug: Postdiagnosis aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postdiagnosis aspirin use (≤ 1 maximum defined daily dose)
Trial: 33942350
Drug: Postdiagnosis aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postdiagnosis aspirin use (> 1 maximum defined daily dose)